达尔奈多
达尔奈多(INN:dalzanemdor;开发代号:SAGE-718)是一种正在研究用于治疗神经系统疾病和认知障碍的实验性药物,[1]是神经甾体脑甾醇的类似物。[2]截至2022年,它在阿尔茨海默病、[3][4][5]帕金森病和亨丁顿舞蹈症[6][7]的治疗上处于二期临床研究阶段。
临床资料 | |
---|---|
其他名称 | SAGE-718 |
法律规范状态 | |
法律规范 |
|
识别信息 | |
| |
CAS号 | 2311911-06-3 |
PubChem CID | |
KEGG | |
ChEMBL | |
化学信息 | |
化学式 | C26H41F3O2 |
摩尔质量 | 442.61 g·mol−1 |
3D模型(JSmol) | |
| |
|
参考文献
编辑- ^ Hill MD, Blanco MJ, Salituro FG, Bai Z, Beckley JT, Ackley MA, et al. SAGE-718: A First-in-Class N-Methyl-d-Aspartate Receptor Positive Allosteric Modulator for the Potential Treatment of Cognitive Impairment. Journal of Medicinal Chemistry. July 2022, 65 (13): 9063–9075. PMID 35785990. S2CID 250250073. doi:10.1021/acs.jmedchem.2c00313.
- ^ SAGE-718. ALZFORUM.
- ^ Shapiro L. #AAN2022 – SAGE-718 May Help With Cognitive Function in Alzheimer's. BioNews, Inc. 2022-04-05.
- ^ SAGE-718 in Patients With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease: Results From the Phase 2 LUMINARY Study (PDF). American Academy of Neurology (AAN) 74th Annual Meeting Abstract.
- ^ Castañeda R. Regulatory roundup: Sage Alzheimer's asset likely to progress after Phase IIa completion. Clinical Trials Arena. 2021-11-16 [2022-07-13]. (原始内容存档于2022-05-28).
- ^ Sage Therapeutics Provides Important Update On The Clinical Development Program For Sage's Investigational Drug, SAGE-718.. Huntington's Disease Society of America. 2022-02-22.
- ^ Wexler M. SAGE-718 on FDA Fast Track as Potential Huntington's Disease Therapy. BioNews, Inc. 2021-09-21.
外部链接
编辑这是一篇作用于神经系统的药品小作品。您可以通过编辑或修订扩充其内容。 |